Protalix BioTherapeutics, Inc.
PLX
Rank in Stocks
#16495
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the... Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Share Price
$2.57
Last synced: 2026-11-09
Market Cap
$207.07M
Change (1 day)
1.18%
Change (1 year)
20.66%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Protalix BioTherapeutics, Inc. (PLX)
Category
Healthcare
Operating Margin for Protalix BioTherapeutics, Inc. (PLX)
Operating Margin as of November 2026 TTM: 28.89%
According to Protalix BioTherapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 28.89%. At the end of 2025 the company had an operating margin of -10.43%.
Operating Margin history for Protalix BioTherapeutics, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 28.89% | -376.99% |
| 2025 | -10.43% | -242.10% |
| 2024 | 7.34% | -54.04% |
| 2023 | 15.97% | -158.46% |
| 2022 | -27.32% | -48.80% |
| 2021 | -53.36% | -1,338.05% |
| 2020 | 4.31% | -122.00% |
| 2019 | -19.59% | -65.26% |
| 2018 | -56.39% | -65.57% |
| 2017 | -163.76% | -54.58% |
| 2016 | -360.51% | -33.53% |
| 2015 | -542.39% | 187.92% |
| 2014 | -188.38% | -20.02% |
| 2013 | -235.53% | 566.09% |
| 2012 | -35.36% | -91.88% |
| 2011 | -435.62% | 63.45% |
| 2010 | -266.51% | -96.77% |
| 2009 | -8,239.43% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | -100.00% |
| 2006 | -6,469.33% | 67.63% |
| 2005 | -3,859.33% | 586.60% |
| 2004 | -562.09% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
| 2000 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -98.66% |
US
|
|
| -149.01% | -105.16% |
US
|
|
| 25.57% | -99.11% |
AU
|
|
| 31.23% | -98.92% |
BE
|
|
| 29.35% | -98.98% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Protalix BioTherapeutics, Inc.'s operating margin
What is Protalix BioTherapeutics, Inc.'s operating margin?
Protalix BioTherapeutics, Inc.'s operating margin is 28.89%, as of Nov 2026.
What was Protalix BioTherapeutics, Inc.'s operating margin in 2025?
In 2025, Protalix BioTherapeutics, Inc.'s operating margin was -10.43%, compared with 7.34% in 2024.
How has Protalix BioTherapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Protalix BioTherapeutics, Inc.'s operating margin was highest in 2023 (15.97%) and lowest in 2021 (-53.36%).
How does Protalix BioTherapeutics, Inc.'s operating margin compare with similar companies?
Protalix BioTherapeutics, Inc.'s operating margin (28.89%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.